Avocet Bio
- Biotech or pharma, therapeutic R&D
Avocet Bio is pioneering a revolutionary antiviral approach using CRISPR-Cas13 technology to combat rapidly mutating RNA viruses. Our modular platform precisely targets and degrades viral RNA, providing broad-spectrum protection while minimizing resistance and side effects.
By leveraging tailored delivery solutions, such as inhalable formulations, we aim to transform the global response to viral outbreaks, reducing disease severity, alleviating healthcare burdens, and strengthening public health resilience.
Currently, efforts are made to expand the platform technology to other RNA viruses or to RNA modulation in disease. Our solution represents an advancement in antiviral and RNA-modulating therapeutics, thereby enhancing public health resilience - a biotech company that will make an impact!
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}